The Wall St. Journal reports that Pfizer raised its divided by 10% and expanded its share repurchase plans by up to $10 billion, in an effort “to return some of its cash pile to shareholders.”

This is the same company that settled off-label marketing claims in October for $14.5 million (following a $2.3 billion settlement of related suits). And it’s the same company that agreed last month to pay $60 million to settle allegations of paying bribes to overseas officials.
Let us help you.
Get a free, confidential case review